Endocrine system diseases

Black, Asian and minority ethnic people receive poorer diabetes treatment, study finds

Black, Asian and minority ethnic people receive poorer diabetes treatment compared to white people, research from the University of Surrey has revealed.…

Vitamin D supplementation boosts insulin sensitivity

Vitamin D supplementation increases peripheral insulin sensitivity in people newly diagnosed with or at high risk of type 2 diabetes mellitus, study results published in the European Journal of Endocrinology have shown.…

At last, a new treatment option for diabetes-related chronic kidney disease

Guideline-changing trial results released earlier in 2019 suggest that SGLT2 inhibitors could be a viable treatment solution for patients with diabetes and evidence of kidney damage.…

Avoidable hospital care for patients with diabetes cost the NHS £3bn in 2017/2018, study finds

Hospital treatment for patients with poorly controlled diabetes cost the NHS more than £3bn in avoidable costs in 2017/2018, a study presented at the European Association for the Study of Diabetes’s Annual Meeting in Barcelona, Spain has revealed.…

Binning the sharps: the quest for oral insulin

The pharmaceutical industry has been trying to develop oral formulations of insulin since the 1920s without success, but, over the past few years, several new oral delivery systems have shown promise in clinical trials.…

Most antidepressants reduce mortality for patients with diabetes and depression

Use of certain antidepressants to treat depression in patients with diabetes is associated with a reduction in mortality, according to a population-based study.…

SGLT2 inhibitor lowers risk of kidney failure in type 2 diabetes

Patients with type 2 diabetes mellitus and chronic kidney disease have a lower risk of kidney failure and cardiovascular events if they are treated with canagliflozin, research has confirmed.…

RPS policy on type 2 diabetes calls for full integration of pharmacists across NHS systems

Pharmacists must be fully integrated into the care of people with type 2 diabetes mellitus in England across all care settings, the Royal Pharmaceutical Society has said.…

Immunotherapy delays type 1 diabetes mellitus in high-risk individuals

  Certain individuals at high risk of developing type 1 diabetes mellitis can delay progression to clinical disease by two years or more with a two-week course of teplizumab, according to results of a phase II study.…

Dulaglutide injection reduces risk of cardiovascular outcomes in type 2 diabetes mellitus by 12%

A weekly dulaglutide injection in addition to existing medication reduces the risk of cardiovascular outcomes in individuals with type 2 diabetes mellitus, compared with placebo, a study published in The Lancet has found.…